Episode 214: PREMIUM – two more diabetes treatments that fail us yet again
In episode 214, James and Mike notch the discussion up to a PREMIUM level yet again. We discuss the 2 new gliptin studies, SAVOR-TIMI 53 (saxagliptin) and EXAMINE (alogliptin) and we find that low and behold these medications lower glucose and have no impact on cardiovascular disease. At the end we lament this lack of cardiovascular benefit by singing a chorus of “Another One Bites The Dust”.
Show notes
1) SAVOR-TIMI 53 – saxagliptin and cardiovascular outcomes
September 2, 2013DOI: 10.1056/NEJMoa1307684
2) EXAMINE – alogliptin and cardiovascular outcomes
September 2, 2013DOI: 10.1056/NEJMoa1305889
Listening to this episode is for premium podcast members only. If you already have a membership, login to your account. If you aren't yet a premium subscriber, sign up today!
